Your session is about to expire
← Back to Search
Calcium Channel Blocker
Targeted Medical Therapy for Angina (MVP-ANOCA Trial)
Phase 2 & 3
Recruiting
Led By Jennifer Tremmel, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Must not have
Contraindications to beta-blockers or calcium channel blockers
Acute coronary syndrome less than one week prior to enrolment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5-7 weeks (depending on drug titration period)
Awards & highlights
Summary
This trial aims to see if a specific medical treatment can help improve symptoms and quality of life in patients with chest pain and clear arteries, compared to a fake treatment. Participants will receive either the real treatment
Who is the study for?
This trial is for patients with different types of chest pain (angina) linked to heart issues without blocked arteries. They should have undergone tests confirming the cause of their angina. People who can't take part include those with other significant health problems, pregnant women, or individuals currently on certain medications.
What is being tested?
The study aims to see if targeted drugs like Amlodipine and Nebivolol can help improve symptoms and life quality in angina patients compared to a placebo. Participants will be randomly given either medication or a placebo for 50 days while monitoring their well-being through questionnaires.
What are the potential side effects?
Possible side effects from Amlodipine may include swelling, fatigue, and dizziness; Nebivolol might cause slow heartbeat, nausea, and headaches. The placebo should not have active side effects but could trigger reactions based on patient expectations.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I cannot take beta-blockers or calcium channel blockers due to health reasons.
Select...
I have not had a heart attack or severe heart issue in the last week.
Select...
I have been diagnosed with cardiomyopathy.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5-7 weeks (depending on drug titration period)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5-7 weeks (depending on drug titration period)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Seattle Angina Questionnaire summary score
Secondary outcome measures
EuroQol 5 dimension - 5L index score
EuroQol 5 dimension - 5L index score stratified by specific chest pain endotypes
EuroQol 5 dimension - 5L visual analogue score
+10 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Targeted medical therapyExperimental Treatment2 Interventions
1. Epicardial or microvascular coronary spasm: Amlodipine 2.5mg initial dose, 10mg max dose
2. Coronary microvascular dysfunction: Nebivolol 5mg initial dose, 20mg max dose
3. Myocardial Bridge: Nebivolol 5mg initial dose, 20mg max dose
4. Mixed epicardial/microvascular spasm and coronary microvascular dysfunction/myocardial bridge: Amlodipine 2.5mg initial dose, 10mg max dose; PLUS Nebivolol 5mg initial dose, 20mg max dose
Participants will take their assigned therapy after randomization. Weekly person via in-person visit or telephone is performed to uptitrate therapy to the maximally tolerated dose. After 1-3 weeks, the initial drug titration phase is completed and a final dose reached. Participants are then instructed to take the maximally tolerated dose for an additional 4 weeks to the conclusion of the study.
Group II: PlaceboPlacebo Group1 Intervention
1. Epicardial or microvascular coronary spasm: Placebo
2. Coronary microvascular dysfunction: Placebo
3. Myocardial Bridge: Placebo
4. Mixed epicardial/microvascular spasm and coronary microvascular dysfunction/myocardial bridge: Placebo
Participants will take their assigned therapy after randomization. Weekly person via in-person visit or telephone is performed to uptitrate therapy to the maximally tolerated dose. After 1-3 weeks, the initial drug titration phase is completed and a final dose reached. Participants are then instructed to take the maximally tolerated dose for an additional 4 weeks to the conclusion of the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Amlodipine
2004
Completed Phase 4
~40680
Nebivolol
2008
Completed Phase 4
~3180
Find a Location
Who is running the clinical trial?
Stanford UniversityLead Sponsor
2,448 Previous Clinical Trials
17,492,293 Total Patients Enrolled
American Heart AssociationOTHER
343 Previous Clinical Trials
4,971,448 Total Patients Enrolled
Jennifer Tremmel, MDPrincipal InvestigatorStanford University
Share this study with friends
Copy Link
Messenger